Navega Therapeutics
San Diego, US · Delaware corporation
Navega Therapeutics develops gene therapies using zinc-finger and CRISPR-based epigenome regulation to control gene expression. The company works in the biotech and gene therapy space.
BiotechDeep TechHealthtech
Founders & leadership
FA
Fernando AlemanExecutive Officer, Director
AM
Ana MorenoExecutive Officer, Director
RS
Randy SocolExecutive Officer
Competitors · 10
by search overlapPatSnap17 shared keywordsPatsnap builds an AI-powered platform for R&D, IP, and innovation intelligence, offering tools for patent search, novelty and FTO analysis, patent drafting, and materials and pharma research. It serves R&D leaders, IP professionals, engineers, and scientists across industries including materials, manufacturing, life sciences, pharmaceuticals, and consumer goods.
Thepharmaletter9 shared keywords
Abeona Therapeutics9 shared keywordsAbeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.
Bioworld8 shared keywordsBioWorld publishes news and data on the biopharmaceutical and drug development industry, covering topics such as clinical trials, licensing deals, oncology pipelines, and gene therapies. It serves biopharma and life sciences professionals through industry reporting and market intelligence.
Nava Therapeutics8 shared keywordsNava develops lipid nanoparticles (LNPs) designed to deliver RNA therapeutics to specific organs and cellular targets for genetic medicine applications. The company focuses on addressing unmet medical needs across a range of RNA therapeutic treatments.
Cowles_Investments_StemCentrx8 shared keywordsFierce Biotech is a news publication covering the biotechnology, pharmaceutical, and medtech industries, reporting on clinical trials, deals, venture capital, drug development, and research. It serves industry professionals through articles, special reports, events, webinars, and podcasts.
visit www.jnanatx.com8 shared keywordsJnana Therapeutics operates a chemoproteomics-based drug discovery platform called RAPID to identify small molecule medicines targeting protein binding sites across multiple target classes. Its pipeline focuses on therapies for phenylketonuria (PKU) and immune-mediated diseases.
Thumbnail for Neurona Therapeutics8 shared keywords
Avernatx8 shared keywordsAverna Therapeutics develops non-viral gene delivery technology using lipid nanoparticles and engineered retrotransposons to safely insert genetic instructions into cells. The platform targets genetic medicine applications across a broad range of addressable diseases.
Thumbnail for Constellation Pharmaceuticals8 shared keywords
Companies competing with Navega Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$1.3MraisedJan 2026 · 8 investors · BiotechnologyRule 506(b)
▶$1.3MraisedJan 2026 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Randy SocolExecutive Officer
- Fernando AlemanExecutive Officer, Director
- Ana MorenoExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $1.3M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 7 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $400K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $275.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $624.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $288.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.